Search
Sunshine Biopharma Inc
SBFMAdd to Watchlist
2.700USD
-0.140-4.93%
Close 11-13 16:00（ET）
2.05MMarket Cap
LossP/E TTM
Sunshine Biopharma Inc (SBFM) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to Sunshine Biopharma Inc in the past month.
Buy
0 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
1120.000USD+38125.26%
SBFM Analyst Recommendation Trends
In the current month, SBFM has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SBFM average Analyst price target in the last month is 1120.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
SBFM Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, SBFM EPS is projected to reach -5.800 in FY2026Q4, following reported EPS of -5.201 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2025Q3
FY2025Q4
FY2026Q4
Forecast
--
--
-3.40
-26.00
-54.00
-5.80
Actual
-2.54
-22.91
-5.20
--
--
--
Surprise
--
--
-52.98%
--
--
--
FAQs
What is Sunshine Biopharma Inc's expected revenue for the next quarter?
Sunshine Biopharma Inc's expected revenue is 9.80M.
What is Sunshine Biopharma Inc's price target?
Analysts forecast that Sunshine Biopharma Inc's price target is USD 1.12K, with the highest forecast at USD 1.12K and the lowest forecast at USD 1.12K.
How have Sunshine Biopharma IncSBFM's recent earnings per share performed?
The market expectation was USD -5.20, while Sunshine Biopharma IncSBFM's earnings per share (EPS) for the previous quarter was USD -22.91. EPS for the next quarter is expected at USD -5.80.
What is the analyst rating for Sunshine Biopharma Inc?
Based on the ratings of Sunshine Biopharma Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.